Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25%…
Subcutaneous amycretin phase 1b/2a data on the safety, tolerability and weight loss potential in people with overweight or obesity was…
HONG KONG, June 03, 2025 (GLOBE NEWSWIRE) -- The International Orthodontics Foundation (IOF), in collaboration with the ADA Forsyth Institute…